Home Investors Analyst Coverage

Analyst coverage

Independent investment analysis and research reports on BlinkLab, provided by third-party analysts.

Bioshares, Australia's Independent Biotech Investment Resource

Bioshares, Australia's Independent Biotech Investment Resource

ADHD Breakthrough Expands the Opportunity | Autism Dx1 Advances Towards FDA Approval

Blinklab Positive ADHD results — a major milestone

Morgans Financial - Initiation: "Blink and you will miss important milestones"

Bioshares, Australia's Independent Biotech Investment Resource

Bioshares, Australia's Independent Biotech Investment Resource

Lodge Partners Research Update - Pilot Study Confirms Path to Commerciality

Outstanding USA Pilot Results Set the Path for 2026 FDA Clearance

Bioshares, Australia's Independent Biotech Investment Resource

Revolutionising Autism and ADHD Diagnosis with AI-Powered smartphone technology

Lodge Partners - Initiation Research Report - BlinkLab Ltd (ASX:BB1) ASD & ADHD Diagnostic App

Bioshares, Australia’s Independent Biotech Investment Resource